Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors.

Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Abstract Text:

Marco Mielcarek,Barry E Storer,Brenda M Sandmaier,Mohamed L Sorror,David G Maloney,Effie Petersdorf,Paul J Martin,Rainer Storb,Marco Mielcarek,Barry E Storer,Brenda M Sandmaier,Mohamed L Sorror,David G Maloney,Effie Petersdorf,Paul J Martin,Rainer Storb,Marco Mielcarek,Barry E Storer,Brenda M Sandmaier,Mohamed L Sorror,David G Maloney,Effie Petersdorf,Paul J Martin,Rainer Storb,

We sought to determine whether patients with hematologic malignancies treated by nonmyeloablative hematopoietic cell transplantation (HCT) at a single institution between December 1997 and June 2006 had worse outcomes with grafts from unrelated donors (URDs) (n = 184) compared with HLA-identical related donors (n = 221). The nonmyeloablative preparative regimen consisted of 2 Gy of total body irradiation (TBI) with (78%) or without (22%) fludarabine, along with posttransplantation mycophenolate mofetil (MMF) and cyclosporine (CSa). After adjusting for the HCT comorbidity index, relapse risk, patient age, stem cell source, preparative regimen, previous cytomegalovirus (CMV) infection, and sex mismatch of donor and recipient in multivariate analysis, we found no statistically significant differences between unrelated and related HCT recipients in terms of risk of nonrelapse mortality (NRM; hazard ratio [HR] = 0.98; 95% confidence interval = 0.6-1.6; P = .94), relapse (HR = 1.04; 95% confidence interval = 0.7-1.5; P = .82), or overall mortality (HR = 0.99; 95% confidence interval = 0.7-1.4; P = .94). Overall rates of severe acute and extensive chronic graft-versus-host disease (aGVHD, cGVHD) also were not significantly different between the 2 groups. We conclude that within the limitations of a retrospective study, these results indicate that candidates for nonmyeloablative HCT without suitable related donors may expect similar outcomes with grafts from URDs.

Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Publishing Authors By Initials

M Mielcarek,BE Storer,BM Sandmaier,ML Sorror,DG Maloney,E Petersdorf,PJ Martin,R Storb,M Mielcarek,BE Storer,BM Sandmaier,ML Sorror,DG Maloney,E Petersdorf,PJ Martin,R Storb,M Mielcarek,BE Storer,BM Sandmaier,ML Sorror,DG Maloney,E Petersdorf,PJ Martin,R Storb,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Biology of blood and marrow transplantation : jour

VOLUME: 13

Page Numbers: 1499-507

Journal Abbreviation: Biol. Blood Marrow Transplant.

ISSN: 1083-8791

DAY: 20

MONTH: Dec

YEAR: 2007

Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9600628

Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors.

AFFILIATION: Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington School of Medicine, Seattle, Washington.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Biol Blood Marrow Transplant

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors Related Publications

• Alkyladenine DNA glycosylase (Aag) in somatic hypermutation and class switch recombination.
• An improved method for dog leukocyte antigen 88 typing and two new major histocompatibility complex class I alleles, DLA-88*01101 and DLA-88*01201.
• Brca1 in immunoglobulin gene conversion and somatic hypermutation.
• Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors.
• Denileukin diftitox as prophylaxis against graft-versus-host disease in the canine hematopoietic cell transplantation model.
• Development and in vitro characterization of canine CD40-Ig.
• Donor-specific mononuclear cell transfusion and methotrexate as pretransplant treatment in dogs given DLA-identical marrow grafts after nonmyeloablative conditioning.
• Expression of AID transgene is regulated in activated B cells but not in resting B cells and kidney.
• Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning.
• Failure of donor lymphocyte infusion to prevent graft rejection in dogs given DLA-identical marrow after 1 Gy of total body irradiation.
• Generation of HIV-1-specific CD8+ cell responses following allogeneic hematopoietic cell transplantation.
• Hematopoietic Cell Transplantation Provides an Immune-tolerant Platform for Myoblast Transplantation in Dystrophic Dogs.
• Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission.
• Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences.
• Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation.
• Increased prevalence of CMV gB3 in marrow of patients with aplastic anemia.
• Long-term tolerance to kidney allografts in a preclinical canine model.
• Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.
• Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia.
• Pharmacokinetics of oral mycophenolate mofetil in dog: bioavailability studies and the impact of antibiotic therapy.
• Principles of peripheral blood mononuclear cell apheresis in a preclinical canine model of hematopoietic cell transplantation.
• Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.
• Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
• Scarcity of lambda 1 B cells in mice with a single point mutation in C lambda 1 is due to a low BCR signal caused by misfolded lambda 1 light chain.
• Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.
• Somatic hypermutation and class switch recombination in Msh6(-/-)Ung(-/-) double-knockout mice.
• Stable trichimerism after marrow grafting from 2 DLA-identical canine donors and nonmyeloablative conditioning.
• Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression.
• The immune system as a foundation for immunologic therapy and hematologic malignancies: a historical perspective.
• Treatment of acute leukemia in remission by bone marrow transplantation.